Screening for anti-angiogenic drugs
2015
Massachusetts Institute of Technology, Cambridge, USA
This angiogenesis model utilizing AIM DAX-1 chips is used to investigate factors that are anti-angiogenic. The inhibitors may include chemical entities, proteins, genetic regulators, mechanobiological factors, etc. The device can be used to identify anti-cancer-drugs.
The microfluidic platform (termed the quantitative microfluidic angiogenesis screen, QMAS), that can monitor and quantify cellular behaviours, such as morphological changes, endothelial cell viability, and formation of angiogenic sprouts, depending on the various concentrations of drug applied. This model incorporates a perfusion culture-based system for generating stable concentration gradients in multiple 3D collagen matrices by generating a pressure-driven uniform flow rate through each of the microfluidic channels. These capabilities are demonstrated through a study of the drug bortezomib, known to inhibit angiogenesis in vivo.
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic assay
Roger D. Kamm
Added on: 07-09-2020
[1] https://pubs.rsc.org/en/content/articlelanding/2015/LC/C4LC00866A#!divAbstract
